Abstract: The invention provides novel guanylate cyclase-C agonist peptides and their use in the treatment of human diseases including gastrointestinal disorders, inflammation or cancer (e.g., a gastrointestinal cancer). The peptides can be administered either alone or in combination with an inhibitor of cGMP-dependent phosphodiesterase. The gastrointestinal disorder may be classified as either irritable bowel syndrome, constipation, or excessive acidity etc. The gastrointestinal disease may be classified as either inflammatory bowel disease or other GI condition including Crohn's disease and ulcerative colitis, and cancer.
Abstract: A method for treating a human infected with Aspergillus by using thymosin alpha 1 as an immuno-stimulator in activating dendritic cells. The method is particularly useful in preventing an infection by Aspergillus in an immuno-compromised host being treated with a bone marrow transplantation.
Type:
Grant
Filed:
March 29, 2004
Date of Patent:
June 26, 2012
Assignee:
SciClone Pharmaceuticals, Inc.
Inventors:
Guido Rasi, Enrico Garaci, Francesco Bistoni, Luigina Romani, Paolo Di Francesco
Abstract: Some embodiments relate to analogs of peptides corresponding to class I MHC-restricted T cell epitopes and methods for their generation. These analogs can contain amino acid substitutions at residues that directly interact with MHC molecules, and can confer improved, modified or useful immunologic properties. Additionally classes of analogs, in which the various substitutions comprise the non-standard residues norleucine and/or norvaline, are disclosed.
Type:
Grant
Filed:
June 17, 2005
Date of Patent:
June 19, 2012
Assignee:
MannKind Corporation
Inventors:
Liping Liu, Zhidong Xie, David C. Diamond
Abstract: The present invention relates to methods and compositions for modulating angiogenesis. In particular, the present invention relates to Pigment Epithelial-derived Factor (PEDF) fragments for use in modulating angiogenesis and treating angiogenesis mediated disease.
Abstract: A process for and intermediates in the preparation of canfosfamide and its salts. Some of the intermediates have anticancer activity.
Type:
Grant
Filed:
December 21, 2004
Date of Patent:
June 12, 2012
Assignee:
Telik, Inc.
Inventors:
William A. Boulanger, Dennis L. Edie, Ronan Y. Guevel, Pedro E. Hernandez Abad, R. Jason Herr, Harold Meckler, Steven R. Schow, Pavel E. Zhichkin
Abstract: Use of a compound of formula (I) in which R, R? and R? have the meanings given in the description, optionally in the form of a salt thereof with a pharmaceutically acceptable organic or mineral base, to prepare a pharmaceutical composition for reducing the blood triglyceride, cholesterol and glucose levels.
Type:
Grant
Filed:
November 13, 2007
Date of Patent:
June 12, 2012
Assignee:
Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F.S.p.A.
Abstract: A method and composition for treating a patient suffering from a disease, disorder or condition and associated pain include the administration to the patient of a therapeutically effective amount of a neurotoxin selected from a group consisting of botulinum toxin types A, B, C, D, E, F and G.
Type:
Grant
Filed:
December 2, 2003
Date of Patent:
May 29, 2012
Assignee:
Allergan, Inc.
Inventors:
Kei Roger Aoki, Michael W. Grayston, Steven R. Carlson, Judith M. Leon
Abstract: This invention relates to a novel antibiotic compounds, pharmaceutically acceptable salts and derivatives thereof, and to methods for obtaining such compounds.
Type:
Grant
Filed:
December 19, 2007
Date of Patent:
May 22, 2012
Assignee:
Novartis AG
Inventors:
Matthew J. Lamarche, Jennifer A. Leeds, Phillipp Krastel, Hans-Ulrich Naegeli
Abstract: A therapeutic method for treating a skin wound involving administering to a patient in need thereof a composition containing pharmaceutically effective amounts of the following components: (1) a peptide consisting of the amino acid sequence represented by Ser-Ser-Ser-Arg (SEQ ID NO: 1) or pharmaceutically acceptable salts thereof and (2) a peptide consisting of the amino acid sequence represented by Phe-Gly-Leu-Met-NH2 (SEQ ID NO: 2) or substance P or pharmaceutically acceptable salts thereof, together with a pharmaceutically acceptable additive.
Abstract: Disclosed is a method of making peptide structures that are stable in aqueous and non-aqueous media where a first linear peptide chain comprising alternating D,L- or L,D-amino acids having an N and C termini is joined by at least one turn region to a second linear peptide chain comprising alternating D,L- or L,D-amino acids having an N and C termini. The peptide chains can be joined at the C terminus of one of the linear peptide chains with an N terminus of the other linear peptide chain, a C terminus of one of the linear peptide chains with a C terminus of the other linear peptide chain, or an N terminus of one of the linear peptide chains with an N terminus of the other linear peptide chain.
Type:
Grant
Filed:
August 6, 2008
Date of Patent:
April 24, 2012
Assignee:
The United States of America, as represented by the Secretary of the Navy
Abstract: The invention relates to carrier complexes and methods for delivering molecules to cells. The carrier complexes comprises a molecule and an aromatic cationic peptide in accordance with the invention. In one embodiment, the method for delivering a molecule to a cell comprises contacting the cell with a carrier complex. In another embodiment, the method for delivering a molecule to a cell comprises contacting the cell with a molecule and an aromatic cationic peptide.
Type:
Grant
Filed:
December 4, 2009
Date of Patent:
April 3, 2012
Assignee:
Cornell Research Foundation, Inc.
Inventors:
Hazel Szeto, Kesheng Zhao, Hugh Robertson, Alex Birk
Abstract: The invention relates to (cyclopropylphenyl) phenyloxamides and their physiologically tolerated salts, and their use as a medicament.
Type:
Grant
Filed:
March 16, 2010
Date of Patent:
April 3, 2012
Assignee:
Sanofi-Aventis
Inventors:
Elisabeth Defossa, Thomas Klabunde, Viktoria Dietrich, Siegfried Stengelin, Guido Haschke, Andreas Herling, Johanna Kuhlmann-Gottke, Stefan Bartoschek
Abstract: The present invention relates to fluorocarbon vectors for the delivery of antigens to immunoresponsive target cells. It further relates to fluorocarbon vector-antigen constructs and the use of such vectors associated with antigens as vaccines and immunotherapeutics in animals.
Type:
Grant
Filed:
September 10, 2008
Date of Patent:
March 6, 2012
Assignee:
Immune Targeting Systems Ltd.
Inventors:
Dominique Bonnet, Carlton B. Brown, Bertrand Georges, Philip J. Sizer
Abstract: The present invention provides novel polypeptides comprising heat shock protein 20 (HSP20)-derived polypeptides to treat or inhibit smooth muscle vasospasm, as well to treat and inhibit smooth muscle cell proliferation and migration.
Abstract: Disclosed are peptides that bind to Ang-2. Also disclosed are peptibodies comprising the peptides, methods of making such peptides and peptibodies, and methods of treatment using such peptides and peptibodies.
Abstract: Methods are provided for the preparation of conjugates of a variety of bioactive components, especially proteins, with water-soluble polymers (e.g., poly(ethylene glycol) and derivatives thereof), which conjugates have reduced antigenicity and immunogenicity compared to similar conjugates prepared using poly(ethylene glycol) containing a methoxyl or another alkoxyl group. The invention also provides conjugates prepared by such methods, compositions comprising such conjugates, kits containing such conjugates or compositions and methods of use of the conjugates and compositions in diagnostic and therapeutic protocols.
Type:
Grant
Filed:
September 25, 2003
Date of Patent:
March 6, 2012
Assignee:
Mountain View Pharmaceuticals, Inc.
Inventors:
Alexa L Martinez, Merry R Sherman, Mark G. P. Saifer, L. David Williams
Abstract: The present invention provides novel HSP20-based polypeptides and pharmaceutical compositions thereof, and methods for using such polypeptides and pharmaceutical compositions for various therapeutic uses.
Abstract: The present invention relates to fluorocarbon vectors for the delivery of antigens to immunoresponsive target cells. It further relates to fluorocarbon vector-antigen constructs and the use of such vectors associated with antigens as vaccines and immunotherapeutics in animals.
Type:
Grant
Filed:
February 4, 2010
Date of Patent:
February 7, 2012
Assignee:
Immune Targeting Systems Ltd.
Inventors:
Dominique Bonnet, Carlton B. Brown, Bertrand Georges, Philip J. Sizer
Abstract: The present invention relates to fluorocarbon vectors for the delivery of antigens to immunoresponsive target cells. It further relates to fluorocarbon vector-antigen constructs and the use of such vectors associated with antigens as vaccines and immunotherapeutics in animals.
Type:
Grant
Filed:
February 4, 2010
Date of Patent:
February 7, 2012
Assignee:
Immune Targeting Systems Ltd.
Inventors:
Dominique Bonnet, Carlton B. Brown, Bertrand Georges, Philip J. Sizer
Abstract: Compositions and related methods for treating IBS and other gastrointestinal disorders and conditions (e.g., gastrointestinal motility disorders, functional gastrointestinal disorders, gastroesophageal reflux disease (GERD), duodenogastric reflux, Crohn's disease, ulcerative colitis, inflammatory bowel disease, functional heartburn, dyspepsia (including functional dyspepsia or nonulcer dyspepsia), gastroparesis, chronic intestinal pseudo-obstruction (or colonic pseudoobstruction), and disorders and conditions associated with constipation, e.g., constipation associated with use of opiate pain killers, post-surgical constipation, and constipation associated with neuropathic disorders as well as other conditions and disorders are described. The compositions feature peptides that activate the guanylate cyclase C (GC-C) receptor.
Type:
Grant
Filed:
September 28, 2009
Date of Patent:
January 24, 2012
Assignee:
Ironwood Pharmaceuticals, Inc.
Inventors:
Mark G. Currie, Shalina Mahajan-Miklos, Li Jing Sun